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Abstract
The Human Proteome Organization’s (HUPO) Human Proteome Project (HPP) developed Mass 
Spectrometry (MS) Data Interpretation Guidelines that have been applied since 2016. These 
guidelines have helped ensure that the emerging draft of the complete human proteome is highly 
accurate and with low numbers of false-positive protein identifications. Here, we describe an 
update to these guidelines based on consensus-reaching discussions with the wider HPP 
community over the past year. The revised 3.0 guidelines address several major and minor 
identified gaps. We have added guidelines for emerging data independent acquisition (DIA) MS 
workflows and for use of the new Universal Spectrum Identifier (USI) system being developed by 
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the HUPO Proteomics Standards Initiative (PSI). In addition, we discuss updates to the standard 
HPP pipeline for collecting MS evidence for all proteins in the HPP, including refinements to 
minimum evidence. We present a new plan for incorporating MassIVE-KB into the HPP pipeline 
for the next (HPP 2020) cycle in order to obtain more comprehensive coverage of public MS data 
sets. The main checklist has been reorganized under headings and subitems, and related guidelines 
have been grouped. In sum, Version 2.1 of the HPP MS Data Interpretation Guidelines has served 
well, and this timely update to version 3.0 will aid the HPP as it approaches its goal of collecting 
and curating MS evidence of translation and expression for all predicted ~20000 human proteins 
encoded by the human genome.
Graphical Abstract
Keywords
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Introduction
The Human Proteome Organization’s1 (HUPO) Human Proteome Project2,3 (HPP) was 
launched in 2010 as an international endeavor to build on the success of the Human Genome 
Project4,5 by characterizing the products of the ~20000 human protein-coding genes. As of 
January 2019, 17694 proteins demonstrated compelling mass spectrometry (MS) or non-MS 
protein-level evidence in neXtProt (i.e., PE1), leaving 2129 proteins without strong evidence 
(PE2,3,4) that were have been designated as the HPP’s ‘missing proteins’6. The PE2,3,4 
missing proteins represented 10.7% of all neXtProt’s PE2,3,4 proteins. The goals of the HPP 
are (1) to complete the protein ‘parts’ list, including isoforms, post-translational 
modifications (PTMs), and single amino acid variants, with characterization of their 
functions; and (2) to make proteomics an integral part of all multiomics studies in life 
sciences. The Chromosome-centric HPP (C-HPP) consortium focused largely, but not 
exclusively, on the first two goals7, whereas the Biology and Disease HPP (B/D-HPP) 
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focused largely on the latter goal, while recognizing that many studies will also uncover 
disease-specific or tissue-specific PE2,3,4 missing proteins. The progress in achieving these 
goals has been tracked yearly via a set of published metrics3,8–11 based on the major 
knowledge bases of the HPP, namely, neXtProt12, PeptideAtlas13–15, Human Protein 
Atlas16, and the ProteomeXchange17,18 consortium of proteomics data repositories.
In order to maintain a high standard of quality for the identifications in the compendium of 
human proteins, and to ensure that journal articles and data contributions are reporting with 
equally high standards, a set of MS data guidelines was developed. The inaugural version 
1.0 guidelines were released in 2013 and mandated deposition of data to members of the 
newly formed ProteomeXchange Consortium for proteomics/MS data and other repositories 
for other kinds of biochemical data. Initial progress in protein detection was rapid since 
there were many high abundance proteins present in common samples available to catalog. 
However, it soon became apparent that, as the compendium of proteins commonly seen in 
high abundance became complete, the control of false positives during the hunt for missing 
proteins became imperative. Version 2.1 of the HPP MS Data Interpretation Guidelines was 
developed and published in 201619. These guidelines went beyond data deposition 
requirements, setting out minimum standards for the handling of false discovery rate (FDR) 
in the interpretation of MS data as well as minimum standards to claim the detection of any 
missing protein or protein otherwise not yet found in the HPP KB compendium of detected 
proteins.
Version 2.1 of the guidelines has been in force for the annual Journal of Proteome Research 
HPP Special Issues beginning in 2016. For papers submitted outside the frame of the Special 
Issue, the Editors of the Journal of Proteome Research and increasing numbers of other 
proteomics journals now require these guidelines to be met for all claims of missing protein 
identifications.
In the past year it has become apparent that, despite the advances in proteomics, the 
increased difficulty of detecting the remaining ~10% of the human proteome requires an 
update to the guidelines, as discussed on-line (https://docs.google.com/document/d/
167wLMYshQ3jUPJonxyk6TcOvT8GrZcqYOZAtUGOK29w), in the Bioinformatics Hub 
at the 2018 17th HUPO World Congress in Orlando, USA, at the 2019 21st C-HPP 
Symposium in Saint-Malo, France, and at the 2019 18th HUPO World Congress in Adelaide, 
Australia. In these venues, the leadership of the HPP, along with other interested 
contributors, debated 25 aspects of the existing guidelines for journal articles as well as 
current practices of the pipelines that maintain and refine the resources that comprise the 
HPP KB ecosystem.
Here, we describe the outcomes of these discussions, which are reflected in a refined set of 
guidelines to take the HPP forward. First, we present a revised version 3.0 of the HPP MS 
Data Interpretation Guidelines in the form of a brief one-page checklist and more extensive 
three-page checklist documentation. Next, we discuss the reasoning behind the changes to 
each guideline, often providing the set of options debated. Finally, we discuss the reasoning 
behind the changes to overall HPP policy used by the HPP KB pipeline that tracks and 
disseminates the best-available gathered understanding of the human proteome as the HPP 
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and the global community gear up to tackle the most difficult refractory proteins of the 
human proteome.
Changes to the Guidelines
While version 3.0 of the checklist (Supplementary Material S1) looks similar to the previous 
version 2.1 (https://www.hupo.org/HPP-Data-Interpretation-Guidelines), it contains major 
differences. First, in addition to the requirement of a checkmark to indicate that each 
requirement is fulfilled (or NA for not applicable or NC for not completed, both of which 
require an explanation as to why this is not applicable or complete at the bottom of the 
checklist), a new column requests a location where the pertinent information may be found. 
This will typically be a reference to a page number or a supplementary document. This 
additional information makes it much easier for the journal editors, reviewers, and readers to 
find the section in the submission that fulfills each guideline, which can sometimes be 
difficult and slows reviewing. Such a requirement for page numbers is already common in 
submission checklists for many bioinformatics journals.
A second substantial difference is the reorganization of the guidelines into numbered major 
items and lettered subitems. Whereas the previous version had 15 major items, some of 
which were highly related and needed to be considered together, the latest version has only 9 
major items, but some of those contain subitems that should be considered as a group. We 
hope that this provides a better overall organizational framework and is more user-friendly 
ensuring contributor completion. A few guidelines have been deemphasized by being 
merged with important related guidelines. Two new guidelines have been added, as 
discussed in detail below. In the following paragraphs each guideline will be discussed 
briefly with emphasis on changes since version 2.1.0. There are two parts of the guidelines: 
reports of well-established proteins and reports of claims of novel detection of predicted 
proteins.
Section 1
Guideline 1 remains essentially unchanged as a formal requirement that each manuscript be 
submitted with a filled-in checklist describing the compliance of the manuscript with the 
guidelines. If any manuscript is received for publication without a checklist, the handling 
editors immediately request this be completed before sending any manuscript for review. 
The extended description of Guideline 1 has been augmented to describe the new 
requirement in column two for a page number with line number or paragraph number, or 
other indication of the location (such as a specific supplemental table) of the requested 
information.
Guideline 2 requiring deposition of all data sets into a ProteomeXchange repository has been 
expanded into four subparts because, in the version 2.1 guidelines, these subparts were 
concatenated into one sentence, where compliance suffered. There was a strong tendency for 
authors to fulfill the first part of the requirement and move on without addressing other 
components. In order to avoid this, the four main aspects of the previous guideline 2 have 
been separated into four subitems 2a, b, c, d, which require complete data deposition, 
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deposition of analysis reference files, PXD identifier in abstract, and reviewer credentials, 
respectively.
Guideline 3, requiring the use of the most recent neXtProt release, rather than older versions, 
remains unchanged. Our understanding of the human proteome continues to evolve rapidly 
and the use of older versions may lead to confusion and outdated claims. Generally, 
neXtProt curators update regularly, with their prior January release relied upon for HPP 
Journal of Proteome Research Special Issue data analysis/reanalysis and which effectively is 
reflected as the annual HPP metrics3,6,9–11,20.
Guideline 4 merges all previous FDR-related guidelines (4 – 9 in version 2.1) into a single 
top-level entry with four subitems designed to streamline this section. Previous top-level 
guidelines 7 and 8 request that authors consider that FDR calculations should be reported 
with an appropriate number of significant digits (usually one or two), because they are based 
on several imperfect assumptions, and that the required FDR calculations and implied 
number of wrong identifications should be carefully considered in later analysis of any 
resulting protein list. These points have been merged into part b of guideline 4, which also 
addresses reporting of FDR values. The HPP community seems to understand these aspects 
well and separate items no longer seem necessary.
Section 2
Whereas guidelines 1 to 4 apply to all manuscripts presenting MS data, the following 
guidelines 5 to 9 apply only to manuscripts presenting evidence that could qualify the 
newly-identified proteins for consideration as PE1 in neXtProt or to provide MS evidence 
for PE1 proteins lacking MS data, so classified based on other types of data.
In the previous version of the guidelines, missing protein MS evidence was referred to as 
“extraordinary detection claims”, reminiscent of the aphorism that “extraordinary claims 
require extraordinary evidence”, often credited to Carl Sagan (https://en.wikipedia.org/wiki/
Sagan_standard) or Amos Bairoch (https://en.wikipedia.org/wiki/Amos_Bairoch). The 
phrase “extraordinary detection claims” was confusing to many, so this phrase has been 
replaced by “claims of new PE1 protein detection”. Such claims may apply to one of the 
“missing proteins” currently in neXtProt with protein existence status of PE2,3,4. They may 
apply to a current PE5 protein, although most of these entries are annotated as pseudogenes 
in UniProtKB and additional care should be applied to justify that their detection is not 
merely a variation of the common PE1 protein that the predicted PE5 protein sequences 
closely resemble. Finally, this assignation may apply to a protein not yet listed in neXtProt. 
These might include: (i) an entry not yet manually reviewed in UniProtKB, (ii) a protein 
currently annotated as a lncRNA, (iii) a smORF, or (iv) some other novel protein-coding 
element. There are many new protein entries, including immunoglobulins, in annual releases 
from neXtProt. The first three guidelines are specific to each of three different acquisition 
technologies, whereas the two guidelines that follow apply to all three technologies—DDA, 
SRM, and DIA-MS.
Guideline 5 has become a guideline containing three subitems that merge several previous 
top-level guidelines into a single one focused on requirements for data dependent acquisition 
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(DDA) MS workflows, commonly referred to as “shotgun proteomics”. Part 5a is essentially 
the same as previous guideline 10, which affirms that evidence spectra for new PE1 protein 
detection claims must be high mass-accuracy, high signal-to-noise ratio, and clearly 
annotated with peak interpretations. The previous guideline 11 enjoining authors to examine 
the spectra carefully for telltale signs of misidentification has been appended to the extended 
description of the new subitem “a”, since, although laudable, it was difficult for many 
authors to perform effectively and is less important in the presence of the guideline requiring 
comparison with a synthetic spectrum.
Guideline 5b is similar to the previous guideline 12, seeking clear presentations of synthetic 
peptide spectra that match endogenous peptide spectra. The guideline has been augmented to 
include a recommendation by the guidelines revision team group that spectra derived from 
digested recombinant proteins are suitable substitutes for those MS spectra derived from 
peptides created with peptide synthesizing technologies. The guideline has also been 
amended so that a retention time match between the target and the synthetic peptide are no 
longer required, but rather suggested only if the target and reference are both run on the 
same instrument. The use of public reference spectra from synthetic peptides such as from 
SRMAtlas21 is now specifically allowed.
Guideline 5c is completely new. A persistent problem with discussions about the merits of 
certain spectra as evidence for new PE1 protein detection claims is the general inability to 
identify specific spectra and access them easily in the data repositories for close 
examination. PDF representations of MS spectra found in supplementary materials are 
useful but resist close examination and the application of KB tools that reviewers or readers 
might like to use for inspection of presented MS evidence. Furthermore, if reprocessing of 
the data set does not yield the same result, it is very difficult to assess what became of the 
key spectrum and why it does not reveal the same PSM in reprocessing. In order to solve this 
problem, the HUPO Proteomics Standards Initiative22–24 (PSI) has developed the Universal 
Spectrum Identifier (USI) concept as a multi-part key that can universally identify any 
acquired spectrum in a manner that any repository containing the data set would be able to 
display or furnish the same spectrum via this identifier. Guideline 5c now introduces a 
requirement for the provision of USIs for all spectra that provide evidence for new PE1 
protein detection claims, natural sample observations and synthetic peptide spectra alike. 
See http://psidev.info/USI for more information on how to create and use USIs.
Guideline 6 is the same as guideline 13 in version 2.1. It applies to selected/multiple reaction 
monitoring (SRM/MRM) workflows25, requiring that chromatogram traces of the detected 
peptides be provided along with the matching chromatograms of heavy-labeled reference 
synthetic peptides. It is important in SRM that both the intensity patterns and the retention 
times match, since there are typically far fewer ions monitored than peaks available in full 
spectra. We have added a request that the heavy-labeled reference peptides should be spiked 
in at an abundance similar to the target peptides so that minor impurities in the reference do 
not contribute to the target signal. If the heavy-labeled spike-in has a 1% impurity in the 
form of light peptide, then, if the reference is spiked in at 100 times the target peptide 
abundance, the impurity will contribute as much signal as the target peptide, leading to an 
incorrect abundance or even a spurious detection. The extended description reaffirms that 
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guidelines 8 and 9 also apply to SRM as there has been some confusion previously. This 
same guideline can also be applied to parallel reaction monitoring26 (PRM) data, although 
since PRM acquisition creates full MS/MS spectra, full compliance with guideline 5 is also 
acceptable.
Guideline 7 is a new guideline that addresses untargeted data independent acquisition (DIA) 
workflows such as SWATH-MS27 and similar techniques28. The version 2.1 guidelines were 
silent on DIA data sets as we felt that the technology was too new to write useful guidelines 
at that time. In the meantime, DIA has become a broadly-adopted technology. Although DIA 
has not yet been used to claim detection of new PE1 proteins, this will surely come. 
Guideline 7 is simple. It applies guidelines 5 and 6 depending on the mode of bioinformatics 
analysis of the DIA data. If the data are analyzed via extracted ion chromatograms (XICs) 
(sometimes called peptide-centric analysis) such as with OpenSWATH29, Spectronaut30, and 
SWATH 2.0, then the SRM guideline 6 applies. If the data are analyzed via extracted 
demultiplexed spectra (sometimes called spectrum-centric analysis) such as with DIA-
Umpire31 and DISCO, then the DDA guidelines 5a-c apply. The next few years will show 
whether DIA can be used reliably for new PE1 detection claims and if this simple approach 
to a DIA guideline is sufficient. Of interest is the observation that the journal Molecular and 
Cellular Proteomics has recently developed a comprehensive set of guidelines for handling 
DIA data32. Authors are advised to examine these and use these where applicable to further 
support claims, although as yet they are not required as part of the HPP and/or Journal of 
Proteome Research guidelines.
Guideline 8 remains the same as the previous guideline 14, encouraging authors to consider 
alternate explanations for novel spectral matches. In many cases a single amino acid variant 
(SAAV) or a post-translational modification (PTM) creates an isobaric or near-isobaric 
change that can mean the difference between mapping to a protein never before detected 
with MS and a common protein observed by millions of PSMs. Despite some useful tools 
available for authors to address this guideline (e.g., neXtProt peptide uniqueness checker33 
and PeptideAtlas ProteoMapper34), it remains one of the most difficult to fulfill, since exact 
mappings are clear enough, but near mappings are difficult and time consuming to assess. 
Nevertheless, the authors consider that this remains an important guideline that researchers 
and reviewers should continue to consider when presenting new PE1 protein detection 
claims.
Guideline 9 is a derivative of the previous guideline 15, although many aspects were 
discussed extensively and several small modifications made. This guideline provides the 
minimum MS requirements for the number and attributes of peptides that support the claim 
of any new PE1 protein detection. The group reaffirmed that two uniquely-mapping, non-
nested peptides of nine or more amino acids should be the minimum required for such a 
claim. However, various aspects of this requirement were discussed extensively and 
clarifications made. First, the definition of non-nesting was clarified. Strictly, the meaning of 
non-nested means that one peptide may not be completely contained within another. The 
reasoning is that, although the observation of two nested peptides increases the confidence 
that the peptides have been correctly identified, it does not provide any additional evidence 
that the peptide has been correctly mapped to the protein in question; i.e., if the longer 
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peptide is mismapped and should instead map to some part of the proteome that we do not 
yet fully understand (such an immunoglobulin or some other variation), then the nested 
peptide will have exactly the same problem, and provides no new information. An extension 
of one peptide beyond the other provides some additional mapping confidence. However, the 
previous guidelines as written permitted even a single amino acid extension. For example, a 
tryptic peptide PEPTIDESR and a LysargiNase35 (that cleaves before K/R instead of after 
K/R) peptide KPEPTIDES would qualify as non-nested under the previous guidelines. We 
recommend amendment of the guidelines to require that the total extent of the coverage of 
the two nested peptides combined be at minimum 18 amino acids (2 × 9). This strategy had 
already been implemented at neXtProt, and thus there is no change there, but does reflect a 
change for PeptideAtlas and other interpretations of the guidelines.
Guideline 9 now also contains a clarification for how to handle identical proteins. There are 
118 entries in the current January 2019 neXtProt release that have the same protein sequence 
for at least one other entry. These entries reflect different gene loci that may have 
synonymous-coding nucleotide variation but yield the exact same protein sequence. This is 
an extreme case of highly homologous proteins. These 118 entries can be retrieved by 
applying the SPARQL query NXQ_00231 (https://www.nextprot.org/proteins/search?
mode=advanced&queryId=NXQ_00231) in the neXtProt advanced search tool. They 
represent a total of 51 distinct protein sequences. It was decided that for the purposes of PE 
status assignment, if two or more qualifying peptides map uniquely to multiple identical 
proteins, then all such proteins will be switched to PE1 as a group since they are 
indistinguishable from each other. Nonetheless, it was noted that since their gene promoter 
regions are likely to differ, these proteins may be expressed in different tissues, or under 
different spatiotemporal circumstances or under different physiological or pathological 
conditions. As is the case now, each will be counted individually as PE1.
The group further clarified that, while the two peptides presented as evidence do not need to 
originate from the same sample or instrument, they do need to be presented together in the 
paper. The practice of offering a single new suitable peptide to complement a pre-existing 
different suitable peptide already in PeptideAtlas and neXtProt is permitted, but the 
PeptideAtlas peptide spectrum must also be scrutinized and compared with a synthetic 
peptide spectrum in accordance with the above guidelines with all evidence presented in the 
paper.
Changes to the HPP PE2,3,4 Missing Protein Strategy
The current basic process by which the HPP investigators manage the process of reducing 
the number of missing proteins of the human proteome, herein called the “HPP pipeline”, 
begins with the collection of MS data sets from the global community and deposition in one 
of the ProteomeXchange repositories. The vast majority of data sets are deposited into 
PRIDE36,37, with some routed through MassIVE38 and jPOST39. These data sets may come 
from experiments presented in HPP special issues such as this issue, or from experiments 
performed by other members of the community in pursuit of their own research objectives. 
After ProteomeXchange deposition, PeptideAtlas collects raw MS data files and reprocesses 
those data using the tools of the Trans-Proteomic Pipeline (TPP)40–42. Thresholds are set 
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extremely high in PeptideAtlas in order to obtain a 1% protein-level FDR across the 
ensemble of all data sets. In November each year, PeptideAtlas stops processing new data 
sets and creates an annual build reflecting the current state of the human proteome from MS 
evidence. In December the final peptide list is transferred to neXtProt for integration into 
neXtProt’s next build/release based on their import of the most recent version of the human 
proteome from UniProtKB/Swiss-Prot. While all peptides that pass thresholds are visible in 
PeptideAtlas and neXtProt, only the proteins with two uniquely-mapping non-nested 
peptides with length 9 amino acid (AA) or greater, as called by neXtProt, are deemed to 
have sufficient evidence to be labeled as confidently detected PE1 proteins by MS methods. 
Therefore, neXtProt is the final arbiter to decide if a PE2,3,4 protein in UniProtKB is 
deemed PE1 in neXtProt and released as such for HUPO’s HPP. Figure 1 provides a 
graphical summary of the current HPP pipeline.
The group discussed several ambiguities and refinements of this process and made 
recommendations/decisions on how the HPP pipeline will be defined for the next few years. 
The group also sought to clarify some terminology pertaining to peptides relevant to the 
HPP Pipeline process, most notably the term “stranded peptide”, which has been used in 
several different (possibly confusing) contexts in the past43,44. After considerable 
discussion, it was resolved that the term “stranded peptide” shall specifically refer to “a 
peptide that meets the minimum length and mapping uniqueness requirements and has 
publicly available evidence for its detection via MS, but the evidence is not within the HPP 
Pipeline”. In order to become unstranded, this publicly available information must be 
captured and validated by the HPP Pipeline. In addition, the term “singleton peptide” shall 
refer to a peptide that meets the minimum length and mapping uniqueness requirements but 
does not have the needed additional partner peptide to achieve the full requirements for two 
non-nested peptides. Stranded peptides may be singletons or not; singleton peptides may be 
stranded or not. This terminology is used further below.
The first refinement is for how SAAVs are handled with respect to mapping uniqueness. The 
fundamental question is what degree of mutation should be considered when mapping 
potentially uniquely-mapping peptides to the proteome. Should all SAAVs in neXtProt be 
considered when mapping peptides, and in all permutations (e.g., if there are three annotated 
mutation sites in a single peptide, should mapping all three residues that are mutated be 
considered, or should just one at a time be considered)? Despite substantial diversity in 
opinion, the consensus was that co-occurrence of nearby SAAVs was very low, and therefore 
simply considering one mutation per peptide was sufficient. All mutations in neXtProt, 
except for the somatic mutations from COSMIC45, will be considered during mapping of 
peptides to proteins.
The group discussed whether there should be some formal adjustment to the lower limit 
requirement of two peptides of nine amino acids or longer. These requirements are designed 
to ensure a certain level of confidence in the MS detection of missing proteins, but this level 
was never really quantified in a way to justify that 2 × 9 should be sufficient, but (2 × 8) or 
(3 × 8) or (1 × 9) + (1 × 8) + (1 × 7) should not. An example of the latter comes in the form 
of the current state of the protein Q8N688 β-defensin 123, which has multiple detections of 
7 AA, 8 AA, and 9 AA peptides as shown in Figure 2 and is claimed by Wang et al46. 
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Because this protein is only 67 amino acids long, and the mature form is only 47 AAs long 
after cleaving off the 20 AA-long signal peptide, these are the only three tryptic peptides that 
can be expected. The obvious question is: should this complete MS evidence be sufficient 
for PE1 status assignment? After substantial discussion, it was decided that there would be 
no change to the 2 × 9 policy for now, because building in a more intricate limit without a 
mathematical/statistical foundation for doing so was inadvisable. It was deemed that the 2 × 
9 policy was simple and clear and worth retaining in the absence of a more compelling lower 
limit. However, two future courses of action were recommended.
First, a sounder justification for the lower limit should be sought, perhaps one where a single 
probability formed the lower bound, and there might be multiple combinations that can 
achieve this probability. This would likely yield a per-protein metric since it is far easier and 
far more likely to obtain peptides that map to a very long protein than a very short one. In 
many cases, the use of multiple proteases might be needed to overcome the limitation of 
reliance on tryptic peptides, as might use of semitryptic and N- or C-terminal peptides (see 
below and the 2018 HPP metrics3).
Second, guidelines v2.1 contained an “exceptions clause” for consideration of special cases. 
However, no mechanism was defined or implemented to deal with these special cases until 
now. The group recommended that a dedicated expert panel be formed by the HPP 
Knowledge Base Pillar Committee to judge whether particular proteins (including short 
proteins) that do not meet the guidelines precisely as written may indeed have sufficient 
evidence to meet the HPP’s desired level of confidence for PE1 status assignment. For each 
of the proteins recommended as candidates for elevation to PE1 without the minimum MS 
evidence, the panel would review the available spectra and prospects for obtaining additional 
MS evidence. In some cases, useful confirmatory non-MS evidence may exist. If the 
obtainable evidence is excellent despite not meeting the guidelines and further MS evidence 
is deemed unlikely, such proteins could be proposed by the panel to neXtProt for assessment 
as PE1. β-Defensin 123 (gene name DEFB123) shown above was a prime initial exemplar 
candidate for the expert panel to consider.
The group discussed whether there are any proteins that should be declared too difficult and 
unachievable, and should therefore be simply removed from the denominator of the ratio 
describing the fraction of detectable proteins in the human proteome identified as PE1 
proteins. As an example, there are 15 proteins which cannot generate two uniquely mapping 
2 × 9 peptides even when using a series of five different common proteolytic enzymes 
(trypsin, LysargiNase, GluC, AspN and chymotrypsin). See Supplemental Table 1 for a list 
of these proteins. Should such proteins be declared unattainable with MS technologies? 
Remarkably, of these 15, nine are already designated as PE1, one of which (C9JFL3) has 
remarkably good non-protease-specific peptides from N and C termini as depicted in Figure 
3. This is common when a protein is highly abundant in a sample. Thus, the group decided 
that no proteins would be declared too difficult now since, if enriched or purified to 
sufficient abundance, many might be accessed from the termini with the aid of non-specific 
cleavages (e.g., through carboxypeptidases). Enrichment of PTM-containing proteins, such 
as shown with SUMOylation3,47 may also be especially effective here.
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A related and difficult class of proteins is the olfactory receptors. There are four PE1 entries 
based on non-MS evidence, and 401 PE2,3,4 entries that are annotated as being olfactory 
receptors in neXtProt. None of these has the requisite 2 × 9 uniquely mapping peptides 
found in PeptideAtlas. Of the 401 entries, 15 do have a single peptide mapping to them. 
However, a manual inspection of the available spectral evidence indicates that none of these 
can be called a solid detection. In most cases spectra are questionable or too short to be 
confident about the mapping. In all, the meager evidence for olfactory receptor proteins is 
far more consistent with false positives than real MS detections. This is perhaps moot since 
the evidence as is does not meet the guidelines but serves as an important reminder that 
PeptideAtlas does contain some false positives, and additional stringency of multiple 
detections and expert review of spectra are required for high confidence. The null hypothesis 
therefore remains that, among all 1500+ samples collated in the PeptideAtlas build, there are 
zero credible detections of olfactory receptors despite some previous hints to the contrary48. 
Interestingly, if it is accepted that there have been zero credible detections of olfactory 
receptors via MS, one can use the putative matches to olfactory receptors in any data set to 
provide an independent estimate of the true FDR of the data set. In any case, after substantial 
discussion, the group felt that, although detection of olfactory receptors by MS has proven to 
be extremely refractory49, it should not be insurmountable, and efforts should continue. The 
successful detection will likely require isolation of the most appropriate olfactory cilia 
membrane samples, high levels of detergent to free these proteins from the membrane, 
enrichment with affinity reagents, and finally detection via MS of the enriched protein 
sample — a difficult challenge indeed. If transcript levels are extremely low and expression 
of any single of the ~400 olfactory receptors is tightly limited to only one receptor in any 
cell at any time, detection may be not feasible due to limit of detection of current MS and 
possibly antibody-based methods.
The final major proposed change to the HPP pipeline is the addition of MassIVE-KB38 to 
the workflow. Whereas the current HPP pipeline (as described above and shown in Figure 1) 
includes only PeptideAtlas as the data set reprocessing engine, it was agreed that adding 
MassIVE-KB as a second reprocessing engine may have substantial benefits. While data sets 
reprocessed in both PeptideAtlas and MassIVE-KB have substantial overlap, this is not 
100% and since MassIVE-KB has similar stringency criteria as PeptideAtlas, HPP output 
quality levels would be expected to be similar. Yet, it is known that there are protein 
detections in MassIVE-KB that meet the same criteria used by PeptideAtlas and neXtProt 
that should be captured by the HPP Pipeline38. To guard against the possible doubling of 
FDR by combining these resources, the HPP Pipeline will require that minimal evidence for 
a PE1 protein (i.e. two uniquely mapping non-nested peptides of length 9AA or more) must 
come from either PeptideAtlas or Massive-KB, but not a mixture of peptides from each. In 
other words, combining a singleton peptide from one resource with a singleton from the 
other resource will not be deemed sufficient until all evidence is reprocessed and validated 
by a single resource within the HPP Pipeline.
Conclusion
As the HPP approaches one of its major initial goals (achieving credible detection of all 
proteins coded by the human genome), the HPP MS Data Interpretation Guidelines that 
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served the project well since 2016 have now been clarified and enhanced with broad 
consensus of the HPP leadership. These revisions address some previous ambiguities that 
have emerged and address issues that seemed insignificant when the goal was distant. The 
new guidelines provide an enhanced framework for ensuring that the evidence used to 
substantiate future protein detection claims remains of very high quality. As such we trust 
they will help guide the global proteomics community on the path to missing protein 
discovery and functional understanding of proteins in the full biological detail of their 
spatiotemporal networks, pathways, molecular complexes, transport, and localization.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Overview of the 2019 HPP pipeline for data integration. HPP investigators publish their 
results constrained by the HPP guidelines. The data sets from these publications as well as 
other data sets from the community flow into the ProteomeXchange repositories. Currently a 
subset of the data sets from PRIDE, MassIVE, and JPOST are reprocessed by PeptideAtlas, 
the results of which are transferred to neXtProt constrained by the HPP guidelines. 
Information from PeptideAtlas, neXtProt, and Human Protein Atlas is summarized yearly in 
the HPP Metrics summary (this issue). Data from the Human Protein Atlas is also 
transferred to and reprocessed by neXtProt as part of the HPP data cycle, although they are 
not yet used to change PE status.
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Depiction of the current status of Q8N688 Beta-defensin 123. The protein is only 47 AAs 
long after cleavage of the 20 AA signal peptide. Three distinct peptide sequences are 
detected (plus a fully nested peptide), but only one of the three meets guideline length 
requirements. Yet, all of the expected tryptic peptides (plus one missed cleavage product) are 
detected with excellent spectra. Should this be sufficient?
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Depiction of the current status of C9JFL3, currently annotated as “Proline, histidine and 
glycine-rich protein 1”. The protein is 83 amino acids long, but produces no useful fully 
tryptic peptides—only one that is too short and one that is too long. Yet, due to its high 
abundance in some samples, many miscleaved peptides are detected, easily providing the 
minimum evidence. The red bars indicate well detected peptides in PeptideAtlas. Multiple 
semitryptic peptides originate from the only cleavage site after the sixth amino acid. 
Multiple nontryptic peptides originate from the C terminus.
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